Human helminth therapy to treat inflammatory disorders- where do we stand?

被引:120
作者
Helmby, Helena [1 ]
机构
[1] London Sch Hyg & Trop Med, Dept Immunol & Infect, Fac Infect & Trop Dis, London WC1E 7HT, England
关键词
Helminths; Inflammation; Regulation; Autoimmunity; PLACEBO-CONTROLLED TRIAL; TRICHURIS-SUIS THERAPY; IMMUNE-RESPONSES; HOOKWORM INFECTION; PARASITE INFECTION; COMMUNITIES; PREVALENCE; PRODUCTS; DISEASE; ALLERGY;
D O I
10.1186/s12865-015-0074-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Parasitic helminths have evolved together with the mammalian immune system over many millennia and as such they have become remarkably efficient modulators in order to promote their own survival. Their ability to alter and/or suppress immune responses could be beneficial to the host by helping control excessive inflammatory responses and animal models and pre-clinical trials have all suggested a beneficial effect of helminth infections on inflammatory bowel conditions, MS, asthma and atopy. Thus, helminth therapy has been suggested as a possible treatment method for autoimmune and other inflammatory disorders in humans.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Dupuytren's disease: where do we stand?
    Grazina, Rita
    Teixeira, Sergio
    Ramos, Renato
    Sousa, Henrique
    Ferreira, Andreia
    Lemos, Rui
    [J]. EFORT OPEN REVIEWS, 2019, 4 (02): : 63 - 69
  • [32] The gut microbiota in osteoarthritis: where do we stand and what can we do?
    Xiaoxia Hao
    Xingru Shang
    Jiawei Liu
    Ruimin Chi
    Jiaming Zhang
    Tao Xu
    [J]. Arthritis Research & Therapy, 23
  • [33] The gut microbiota in osteoarthritis: where do we stand and what can we do?
    Hao, Xiaoxia
    Shang, Xingru
    Liu, Jiawei
    Chi, Ruimin
    Zhang, Jiaming
    Xu, Tao
    [J]. ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [34] Therapeutic Approaches toward Multiple Sclerosis: Where Do We Stand and Where Are We Headed?
    Moura, Rui Pedro
    Sarmento, Bruno
    [J]. ADVANCED THERAPEUTICS, 2019, 2 (10)
  • [35] Herbal drugs-loaded soft nanoparticles for treating skin disorders: Where do we stand?
    Reolon, Jessica Brandao
    Sari, Marcel Henrique Marcondes
    Marchiori, Crisleine
    Dallabrida, Kamila Gabrieli
    dos Santos, Jaqueline Aparecida Rodrigues
    de Almeida, Isabela de Fatima Ramos
    Alves, Fernando Miguel Stelmach
    Bonini, Juliana Sartori
    Ferreira, Luana Mota
    [J]. INDUSTRIAL CROPS AND PRODUCTS, 2023, 206
  • [36] Inflammation, infection and antimicrobial therapy in coronary heart disease - where do we currently stand?
    Ngeh, J
    Gupta, S
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 (02) : 85 - 93
  • [37] Cancer screening in the aging population: Where do we stand and what can we do?
    Cao, Wei
    Chen, Wanqing
    [J]. JOURNAL OF THE NATIONAL CANCER CENTER, 2022, 2 (03): : 127 - 129
  • [38] Immunomodulation in Polytrauma and Polymicrobial Sepsis - Where Do We Stand?
    Neunaber, Claudia
    Zeckey, Christian
    Andruszkow, Hagen
    Frink, Michael
    Mommsen, Philipp
    Krettek, Christian
    Hildebrand, Frank
    [J]. RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2011, 5 (01) : 17 - 25
  • [39] Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
    Hu, Li-Feng
    Lan, Huan-Rong
    Huang, Dong
    Li, Xue-Min
    Jin, Ke-Tao
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [40] Statins in Heart Failure-Where Do We Stand?
    Lyons, Kristopher S.
    McVeigh, Gary E.
    Harbinson, Mark T.
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2011, 25 (01) : 99 - 104